VBIO (Valion Bio) LT-Debt-to-Total-Asset: 0.43 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VBIO Valion Bio Inc VBIO
23 GF Score
Price $0.30
! 1 Warning Sign
View Full Analysis

What is Valion Bio LT-Debt-to-Total-Asset?

Valion Bio VBIO +2.76% 23 LT-Debt-to-Total-Asset is 0.43 as of Mar. 2026. GuruFocus rates VBIO with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Valion Bio's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.43.

Valion Bio's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.43). It may suggest that Valion Bio is progressively becoming more dependent on debt to grow their business.

Valion Bio  (NAS:VBIO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Valion Bio LT-Debt-to-Total-Asset Related Terms

Valion Bio LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Valion Bio's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valion Bio LT-Debt-to-Total-Asset Chart

Valion Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.04 0.06 0.03 0.00 0.20

Valion Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.20 0.43
VBIO
23GF Score
Valion Bio Inc VBIO
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valion Bio LT-Debt-to-Total-Asset Calculation

Valion Bio's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=6.454/31.607
=

Valion Bio's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=16.542/38.215
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.43 mean?
Valion Bio (VBIO) has a LT-Debt-to-Total-Asset of 0.43 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Valion Bio and its competitors.
Is Valion Bio's LT-Debt-to-Total-Asset too high?
Valion Bio's current LT-Debt-to-Total-Asset is 0.43. Overall, Valion Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Valion Bio's LT-Debt-to-Total-Asset compare to ZVSA and LYRA?
Valion Bio's LT-Debt-to-Total-Asset of 0.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Valion Bio and its competitors. Valion Bio's current LT-Debt-to-Total-Asset is 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valion Bio stock overvalued right now?
Valion Bio (VBIO) has a current LT-Debt-to-Total-Asset of 0.43. The current LT-Debt-to-Total-Asset is 0.43. Valion Bio's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Valion Bio (VBIO), the current LT-Debt-to-Total-Asset is 0.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valion Bio Business Description

Address 1305 East Houston Street, Suite 311, Building 1, San Antonio, TX, USA, 78205
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
23GF Score

Get the complete analysis for VBIO

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price